Showing 281-290 of 346 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| The T1D Parent Check-In: A Preventative Intervention | Massachusetts General Hospital | Ellen O’Donnell | Improving Lives | 01-July-2023 to 01-September-2026 | $390.792,17 |
| Development of a Microfluidic Patch Pump for Next-Generation Wearable Artificial Pancreas Systems | University of California, Santa Barbara | Sumita Pennathur | Improving Lives | 01-May-2023 to 30-April-2026 | $1.065.254,36 |
| Type 1 Diabetes Consortium – Core and Prevention Workstream | Critical Path Institute (C-Path) | Sarah David | Cures | 01-July-2022 to 30-June-2025 | $800.270,00 |
| Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth | Johns Hopkins University | Risa Wolf | Improving Lives | 01-January-2023 to 31-December-2026 | $637.547,20 |
| Evaluating the Initial Efficacy, Acceptability, and Feasibility of BFST-DT, an Intervention for Improving Transition Readiness for Adolescents and Emerging Adults with Type 1 Diabetes | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jaclyn Papadakis | Improving Lives | 01-May-2023 to 30-April-2027 | $396.471,68 |
| Addressing and mitigating sources of variability for the controlled and automated manufacturing of stem cell-derived beta (SC-beta) cells from pluripotent stem cells (PSCs) | Advanced Regenerative Manufacturing Institute (ARMI) | Thomas Bollenbach | Cures | 01-January-2023 to 31-December-2026 | $1.241.255,20 |
| Antigenic Targets of CD4 T cells across the stages of type 1 diabetes | Regents of the University of Colorado | Maki Nakayama | Cures | 01-August-2022 to 31-July-2026 | $750.000,00 |
| Localized immune modulation to enable long-term beta cell survival | William Marsh Rice University | Omid Veiseh | Cures | 01-September-2022 to 31-January-2026 | $596.642,49 |
| A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-September-2022 to 01-January-2026 | $273.424,00 |
| Real time monitoring of a cell therapy product to assess and modify transplant health post-engraftment in patients with type 1 diabetes | Minutia | Katy Digovich | Cures | 01-November-2022 to 31-March-2026 | $1.198.600,00 |